Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Steven Seedhouse
MD & Biotechnology Analyst

Okay. Well, thanks so much, everyone, and welcome to the next session. I’m Steve Seedhouse from the biotech team here at Cantor. And it’s really a privilege for me to introduce our next presenting company, Pharvaris. I’m joined on stage by CCO, Wim Souverijns; and the CMO, Peng Lu. I’m really looking forward to the conversation.

Obviously, Pharvaris is developing deucrictibant. It’s a very exciting molecule for HAE. And in lieu of me saying more, I would love to maybe pass it off to either Peng or Wim, if you’d like, just to make some opening comments and introduction to the company and to yourselves and sort of where the current state of affairs is at Pharvaris, and then we’ll get right into Q&A.

Wim Souverijns
Chief Commercial Officer

So — and thank you very much for welcoming us here. My name is Wim. I’m the Chief Commercial Officer. So Pharvaris, we are a late-stage pre-commercial biotech company. We’re developing one active ingredient with 2 products for both the treatment and the prevention of bradykinin-mediated attacks.

We’ve got a very exciting period ahead of us because we have data readouts at the end of this year, Q4. We’ll have filing next year. We have another Phase III readout second half of next year. So we’re all gearing up for getting these products to patients, and I’m here together with Peng.

Peng Lu
Chief Medical Officer

Yes. Thanks, Wim. Can you hear me? Great. This is Peng Lu here. I’m the Chief Medical Officer, joined Pharvaris around 2020. Just like Wim mentioned, it’s